Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The advent of biosimilar therapies in rheumatology—“O Brave New World”

Abstract

Patents for many key biological agents will soon expire. Third-party companies are, therefore, in the process of developing their own versions, termed biosimilar agents, of these innovator products. However, manufacture of biosimilar agents is complicated by the requirement for their production in biological systems, small variations in which can influence the structure, activity and metabolism of the biosimilar product. The development of biosimilar therapies for the treatment of patients with rheumatic diseases could potentially result in substantial cost savings for patients and health care providers, and consequently, increased availability of effective therapies. However, legislation that regulates the manufacture, registration and approval of biosimilar therapies varies considerably between different countries. In addition, major safety and efficacy concerns must be addressed before a rheumatologist can routinely substitute an innovator pharmaceutical with a biosimilar product.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Worldwide status of regulations for the approval of biosimilar agents.

References

  1. Hyrich, K. L. et al. Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 56, 13–20 (2007).

    Article  CAS  Google Scholar 

  2. Patent status information—register entry for European Patent 0343684. Intellectual Property Office [online] (2009).

  3. Patent status information—register entry for European Patent 0409607 Intellectual Property Office [online] (2009).

  4. US$54 billion worth of biosimilar patents expiring before 2020. Generics and Biosimilars Initiative Online [online], (2011).

  5. Medtrack [online], (2012).

  6. Publications Office of the European Union. Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products. EUR-Lex [online], (1992).

  7. Castanheira, L. G., Barbano, D. B. & Rech, N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals 39, 308–311 (2011).

    Article  Google Scholar 

  8. Brockhaus, M. et al. Human TNF receptor fusion protein. US Patent 8,063,182 (1995).

  9. Medco Health Solutions, Inc. Estimated dates of possible first time generic/ Rx-to-OTC market entry. Medco [online], (2012).

  10. Kay, J. Biosimilars: a regulatory perspective from America. Arthritis Res. Ther. 13, 112 (2011).

    Article  CAS  Google Scholar 

  11. US Food and Drug Administration. Guidance for Industry. Biosimilars: questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009. Department of Health & Human Services [online], (2012).

  12. Dranitsaris, G., Amir, E. & Dorward, K. Biosimilars of biological drug therapies: regulatory, clinical and commercial considerations. Drugs 71, 1527–1536 (2011).

    Article  CAS  Google Scholar 

  13. Woodcock, J. et al. The FDA's assessment of follow-on protein products: a historical perspective. Nat. Rev. Drug Discov. 6, 437–442 (2007).

    Article  Google Scholar 

  14. McCamish, M. & Woollett, G. Worldwide experience with biosimilar development. MAbs 3, 209–217 (2011).

    Article  Google Scholar 

  15. Mellstedt, H., Niederwieser, D. & Ludwig, H. The challenge of biosimilars. Ann. Oncol. 19, 411–419 (2008).

    Article  CAS  Google Scholar 

  16. Schiestl, M. et al. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat. Biotechnol. 29, 310–312 (2011).

    Article  CAS  Google Scholar 

  17. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. ICH harmonisation for better health [online], (2004).

  18. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products. European Medicines Agency [online], (2005).

  19. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency [online], (2006).

  20. Liang, C. & Wang, J. China's perspective on similar biotherapeutic products. Biologicals 39, 312–316 (2011).

    Article  Google Scholar 

  21. Knezevic, I. & Griffiths, E. Biosimilars—global issues, national solutions. Biologicals 39, 252–255 (2011).

    Article  Google Scholar 

  22. Schellekens, H. & Moors, E. Clinical comparability and European biosimilar regulations. Nat. Biotechnol. 28, 28–31 (2010).

    Article  CAS  Google Scholar 

  23. Committee for Medicinal Products for Human Use. Guideline on similar biological medicinal products containing monoclonal antibodies. Draft. European Medicines Agency [online], (2010).

  24. Committee for Medicinal Products for Human Use. Concept paper on the revision of the guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. European Medicines Agency [online], (2011).

  25. Barosi, G. et al. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica 96, 937–942 (2011).

    Article  CAS  Google Scholar 

  26. US Food and Drug Administration. FDA HR 3590—686. Patient Protection and Affordable Care Act. Title VII—Improving access to innovative medical therapies. Subtitle A—Biologics price competition and innovation. Sec. 7002. Approval pathway for biosimilar biological products. US Department of Health & Human Services [online], (2010).

  27. US Food and Drug Administration. Regulatory information. Sec. 505. [21 USC §355] New Drugs. US Department of Health & Human Services [online], (2009).

  28. Kozlowski, S., Woodcock, J., Midthun, K. & Sherman, R. B. Developing the nation's biosimilars program. N. Engl. J. Med. 365, 385–388 (2011).

    Article  CAS  Google Scholar 

  29. Kessler, M., Goldsmith, D. & Schellekens, H. Immunogenicity of biopharmaceuticals. Nephrol. Dial. Transplant. 21 (Suppl. 5), v9–v12 (2006).

    Article  CAS  Google Scholar 

  30. Health Canada Health Products and Food Branch. Guidance for sponsors: information and submission requirements for subsequent entry biologics (SEBs) Health Canada [online], (2010).

  31. World Health Organization Expert Committee on Biological Standardization. Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization [online], (2009).

  32. Núñez, H. Y. et al. The regulatory framework for similar biotherapeutic products in Cuba. Biologicals 39, 317–320 (2011).

    Article  Google Scholar 

  33. Jailing, D. Xian Janssen launches Remicade in China. PharmAsia News [online], (2007).

    Google Scholar 

  34. Maity, S. et al. A non-innovator version of etanercept for treatment of arthritis. Biologicals. 39, 384–395 (2011).

    Article  CAS  Google Scholar 

  35. Malhotra, H. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation. Biologicals 39, 321–324 (2011).

    Article  Google Scholar 

  36. Dr Reddy's launches Rituxan generic. FDC alerts [online], (2007).

  37. BioXpress therapeutics biosimilar pipeline. bioXPRESS Therapeutics SA [online], (2011).

Download references

Author information

Authors and Affiliations

Authors

Contributions

Both authors contributed equally to researching the data for the article, writing the manuscript, discussions of its content, and review and editing of the manuscript before submission.

Corresponding author

Correspondence to Morton A. Scheinberg.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheinberg, M., Kay, J. The advent of biosimilar therapies in rheumatology—“O Brave New World”. Nat Rev Rheumatol 8, 430–436 (2012). https://doi.org/10.1038/nrrheum.2012.84

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2012.84

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing